Rowan Walrath

Pfizer is working with the Flagship Pioneering spinout Montai Therapeutics to develop small molecules as lung cancer treatments.

Halozyme, a California firm that engineers under-the-skin injectable versions of intravenous drugs, is looking to buy the German pharmaceutical services company Evotec.

Amid controversial health care nominations, execs see Makary as ‘reasonable’

Despite a handful of megarounds, many firms struggled to stay afloat “In many respects,” says Jeffrey Quillen, “2024 was a lot like 2023.”

GSK will pay 4-year-old start-up Rgenta Therapeutics up to $46 million in up-front cash and preoption milestone payments—with the potential for up

Despite a handful of megarounds, many firms struggled to stay afloat

Regeneron-backed start-up has $52 million to begin testing its lead candidate in people

The pharma giant will acquire oral peptide developer Nimble Therapeutics

GEMMA Biotherapeutics will put the money toward rare disease drugs

GEMMA Biotherapeutics will put the money toward rare disease drugs